THE ROLE OF TRT IN THE MANAGEMENT OF HYPOGONADISM AND TRT

THE ROLE OF TRT IN THE MANAGEMENT OF HYPOGONADISM AND TRT
  • Maximise video
  • Maximise slides
  • Slide only
  • 50/50
X
/
[ { "title": "the role of TRT in the management of hypogonadism and TRT: Dispelling the myth", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/01.jpg", "position": "0" }, { "title": "safety concerns over testosterone replacement therapy (TRT)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/02.jpg", "position": "36" }, { "title": "Cardiovascular", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/03.jpg", "position": "89" }, { "title": "Tesosterone and cardiac risk - incidence of coronary heart disease (CHD) higher in men", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/04.jpg", "position": "96" }, { "title": "CV mortality: adjusted survival by quartile of total testosterone in men aged 42-78 yrs in the EPIC-Norfolk Study 1993-2003", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/05.jpg", "position": "137" }, { "title": "The Norway-Tromsø-Study: androgens and the prospective mortality risk", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/06.jpg", "position": "158" }, { "title": "Proportion free of MACE lethality as a function of baseline testosterone in a consecutive series of 1,687 ED subjects", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/07.jpg", "position": "181" }, { "title": "Testosterone and coronary arty disease (CAD)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/08.jpg", "position": "208" }, { "title": "Studies in men with cardiovascular disease", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/09.jpg", "position": "245" }, { "title": "hypogonadism is present in a high proportion of men with CAD", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/10.jpg", "position": "268" }, { "title": "effect of baseline-BT on all-cause mortality in men with proven CHD mean follow-up6.9 years", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/11.jpg", "position": "273" }, { "title": "serum levels of total testosterone in men with cardiac heart failure (CHF) by NYHA Class", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/12.jpg", "position": "346" }, { "title": "pooled odds ratios for adverse CV events of TRT", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/13.jpg", "position": "361" }, { "title": "Adverse events of testosterone therapy in adult men: a systematic review and meta-analysis", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/14.jpg", "position": "474" }, { "title": "Studies in men with CVD", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/15.jpg", "position": "502" }, { "title": "Lipids: LDL and HDL - absolute changes", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/16.jpg", "position": "540" }, { "title": "Inflammation: CRP and TNFα", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/17.jpg", "position": "642" }, { "title": "testosterone replacement could reduce death in men with type 2 diabetes", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/18.jpg", "position": "672" }, { "title": "Testosterone treatment is associated with reduced mortality in men with low serum testosterone levels", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/19.jpg", "position": "734" }, { "title": "Adverse events associated with testosterone administration", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/20.jpg", "position": "778" }, { "title": "Basaria, N Eng J Med 2009: CV-related events", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/21.jpg", "position": "912" }, { "title": "Editorial by William Bremner", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/22.jpg", "position": "965" }, { "title": "Lower testosterone levels predict incident stroke and transient ischaemic attack in oder men", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/23.jpg", "position": "991" }, { "title": "Meta-analysis of placebo-controlled testosterone trials in middle-aged and older men: cardiovascular adverse event rates per 1,000 patient-years", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/24.jpg", "position": "1034" }, { "title": "Testosterone and CV risk", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/25.jpg", "position": "1057" }, { "title": "prostate", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/26.jpg", "position": "1089" }, { "title": "testosterone and prostate cancer risk", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/27.jpg", "position": "1092" }, { "title": "the saturation model", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/28.jpg", "position": "1129" }, { "title": "Pre-treatment testosterone levels predict pathological stage in men with prostate cancer before radical prostatectomy", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/29.jpg", "position": "1172" }, { "title": "Testosterone levels and Gleason Scores in men with prostate cancer before radical prostatectomy", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/30.jpg", "position": "1190" }, { "title": "Effects on the prostate of normalizing testosterone levels in hypogonadal men", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/31.jpg", "position": "1208" }, { "title": "Do high doses of testosterone induce adverse effect in the prostate?", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/32.jpg", "position": "1237" }, { "title": "Effects on the prostate of normalising testosterone levels in hypogonadal men", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/33.jpg", "position": "1256" }, { "title": "IPASS Nebido® - safety data (1,123 men)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/34.jpg", "position": "1311" }, { "title": "Safety parameters: prostate", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/35.jpg", "position": "1355" }, { "title": "Do high doses of testosterone induce adverse effect in the prostate?", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/36.jpg", "position": "1374" }, { "title": "Do high doses of testosterone induce adverse effect in the prostate?", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/37.jpg", "position": "1397" }, { "title": "changes in PSA levels during 36 month of Testogel® treatment", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/38.jpg", "position": "1427" }, { "title": "No significant changes in PSA with 1 year of IM TU therapy", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/39.jpg", "position": "1438" }, { "title": "No significant changes in PSA with 1 year of testosterone treatment* in men with hypogonadism", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/40.jpg", "position": "1450" }, { "title": "PSA and prostate volume during treatment with TE/TU in men with hypogonadism*", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/41.jpg", "position": "1461" }, { "title": "changes in prostate volume with long term TU treatment (Nebido®)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/42.jpg", "position": "1478" }, { "title": "changes in PSA levels in men with hypogonadism undergoing long-term treatment with TU (Nebido®)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/43.jpg", "position": "1492" }, { "title": "testosterone in patients in high risk of PCa", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/44.jpg", "position": "1499" }, { "title": "testosterone in patients in high risk of PCa", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/45.jpg", "position": "1546" }, { "title": "testosterone and lower urinary tract symptoms (LUTS)", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/46.jpg", "position": "1756" }, { "title": "Effects on the prostate normalising testosterone levels in hypogonadal men", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/47.jpg", "position": "1773" }, { "title": "Testosterone and LUTS", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/48.jpg", "position": "1798" }, { "title": "Testosterone and LUTS", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/49.jpg", "position": "1864" }, { "title": "Testosterone and LUTS", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/50.jpg", "position": "1888" }, { "title": "What guidelines say about TRT and the prostate", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/51.jpg", "position": "1900" }, { "title": "EAU guidelines on erectile dysfunction 2010", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/52.jpg", "position": "1955" }, { "title": "Fact from fiction - the prostate", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/53.jpg", "position": "2027" }, { "title": "separating the facts from the myths", "image": "https://hcp.nebido.com/deco/nebido-elements/video-presentation/img/slides/4/54.jpg", "position": "2050" } ]
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Tue, 19/05/2020

Bayer logo